HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysisSantam Chakraborty, Debdeep Dey, Sanjoy Chatterjee et al.|Radiotherapy and Oncology|2022Cited by 42
Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trialSanjoy Chatterjee, Santam Chakraborty, Selvamani Backianathan et al.|Trials|2020Cited by 29
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trialsShelley Potter, Hiroko Bando, J Federmann et al.|npj Breast Cancer|2025Cited by 1
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trialsShelley Potter, Maggie Banys-Paluchowski, Kerry Avery et al.|UCL Discovery (University College London)|2025Cited by 0